A REVIEW OF AGO TUMOR

Molecular typing relies on molecular genetic testing and isn't nonetheless routinely readily available. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple unfavorable) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-sixty seven may be